临床前CDMO研发筛选相关化合物如有产品调研服务, 请致函联系我们
客户展示
临床前CDMO研发化合物筛选
Edicotinib(JNJ-40346527)
中文名称:JNJ-40346527游离态
CAS号:1142363-52-7
分子式: C27H35N5O2 分子量: 461.60
产品形式: Free base
研发状态: Terminated
研发用途: Alzheimer Disease; Mild Cognitive Impairment
研究机构: University of Oxford; Janssen Pharmaceutica
研发日期: April 7 2021
研发阶段: Phase 1
Edicotinib (JNJ-40346527) is a potent, selective, brain penetrant and orally active colony-stimulating factor-1 receptor (CSF-1R) inhibitor with an IC50 of 3.2 nM.
Stenoparib (E7449)
CAS号:1140964-99-3
分子式: C18H15N5O 分子量: 317.34
产品形式: free base
研发状态: Withdrawn
研发用途: Cancer of the Breast
研究机构: The University of Texas Health Science Center at San Antonio
研发日期: Apr-15
研发阶段: Phase 1 : Phase 2
Stenoparib (E7449, 2X-121, MGI25036) is an orally bioavailable, brain penetrable, small molecule dual inhibitor of PARP1/2 and also inhibits PARP5a/5b, otherwise known as tankyrase1 and 2 (TNKS1/2), important regulators of canonical Wnt/β-catenin signaling. It has IC50 values of 1.0 and 1.2 nM for PARP1 and 2, respectively.
Cabozantinib malate
中文名称:卡博替尼苹果酸盐
CAS号:1140909-48-3
分子式: C28H24FN3O5.C4H6O5 分子量: 635.59
产品形式: Malate
研发状态: Recruiting
研发用途: Ewing Sarcoma; Osteosarcoma
研究机构: Children''s Hospital of Philadelphia; Children''s Hospital Colorado; Exelixis; Alex''s Lemonade Stand Foundation
研发日期: October 24 2023
研发阶段: Phase 1
Cabozantinib malate (XL184) is the malate of Cabozantinib, a potent VEGFR2 inhibitor with IC50 of 0.035 nM and also inhibits c-Met, Ret (c-Ret), Kit (c-Kit), Flt-1/3/4, Tie2, and AXL with IC50 of 1.3 nM, 4 nM, 4.6 nM, 12 nM/11.3 nM/6 nM, 14.3 nM and 7 nM in cell-free assays, respectively. Cabozantinib malate (XL184) induces apoptosis.
Erythromycin
中文名称: 红霉素
CAS号:114-07-8
分子式: C37H67NO13 分子量: 733.93
产品形式: Free Base
研发状态: Recruiting
研发用途: Brain Injuries
研究机构: University Hospital Brest
研发日期: March 15 2022
研发阶段: Phase 3
Erythromycin (E-Mycin) is a macrolide antibiotic that has an antimicrobial spectrum similar to or slightly wider than that of penicillin (IC50=1.5 μg/ml).
Cidofovir
中文名称:西多福韦
CAS号:113852-37-2
分子式: C8H14N3O6P 分子量: 279.19
产品形式: Free Base
研发状态: Completed
研发用途: Drug Drug Interaction
研究机构: SymBio Pharmaceuticals
研发日期: November 9 2020
研发阶段: Phase 1
Cidofovir (HPMPC,Vistide,GS 0504) suppresses virus replication by selective inhibition of viral DNA synthesis.
TAK-960
中文名称:TAK960抑制剂
CAS号:1137868-52-0
分子式: C27H34F3N7O3 分子量: 561.60
产品形式: free base
研发状态: Terminated
研发用途: Advanced Nonhematological Malignancies
研究机构: Millennium Pharmaceuticals Inc.
研发日期: Sep-10
研发阶段: Phase 1
TAK-960 is a novel, investigational, orally bioavailable, potent, and selective PLK1 inhibitor that has shown activity in several tumor cell lines, including those that express multidrug-resistant protein 1 (MDR1).
我们的宗旨: 净化, 简洁, 高效Purifying, concise, efficient !我们的口号: 减少中间商赚差价!
即日起可免费注册成为会员, 建立企业产品库, 免费上传产品目录, 企业介绍等. 让你的产品直接呈现给客户.
试运营阶段,所有广告业务5折优惠
分类广告投放
依据化学成分的不同, 针对不同的企业和产品, 我们提供分类产品广告投放.客户展示
优秀企业推荐
